Benzinga · Mar 5, 2026
Canaccord Genuity Maintains Hold on Quantum-Si, Lowers Price Target to $1
Canaccord Genuity analyst Kyle Mikson maintains Quantum-Si (NASDAQ:QSI) with a Hold and lowers the price target from $1.5 to $1.
NASDAQ · QSI
Healthcare · Biotechnology
$0.74
Down-$0.01 (-1.45%)
Updated Sep 11, 2026, 5:09 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
QSI closed at $0.74 after 20 trading sessions, down 6.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $0.75 | $0.755 | $0.7251 | $0.7391 | 1.72M |
| Sep 9, 2026 | $0.7602 | $0.7748 | $0.746 | $0.75 | 1.45M |
| Sep 8, 2026 | $0.7672 | $0.79 | $0.76 | $0.76 | 1.05M |
| Sep 4, 2026 | $0.76 | $0.7742 | $0.76 | $0.766 | 898.78K |
| Sep 3, 2026 | $0.7669 | $0.7862 | $0.76 | $0.761 | 980K |
| Sep 2, 2026 | $0.7586 | $0.785 | $0.75 | $0.761 | 1.62M |
| Sep 1, 2026 | $0.75 | $0.7768 | $0.7499 | $0.7573 | 1.5M |
| Aug 31, 2026 | $0.7787 | $0.78 | $0.763 | $0.7659 | 1.13M |
| Aug 28, 2026 | $0.8219 | $0.822 | $0.77 | $0.78 | 2.42M |
| Aug 27, 2026 | $0.7911 | $0.8337 | $0.79 | $0.8031 | 1.38M |
| Aug 26, 2026 | $0.85 | $0.855 | $0.7901 | $0.7906 | 2.66M |
| Aug 25, 2026 | $0.7888 | $0.859 | $0.7817 | $0.8473 | 4.37M |
| Aug 24, 2026 | $0.80 | $0.83 | $0.7515 | $0.7693 | 3.85M |
| Aug 21, 2026 | $0.7848 | $0.931 | $0.78 | $0.835 | 7.83M |
| Aug 20, 2026 | $0.7666 | $0.8099 | $0.7666 | $0.78 | 3.23M |
| Aug 19, 2026 | $0.7193 | $0.7845 | $0.7193 | $0.7701 | 2.86M |
| Aug 18, 2026 | $0.7325 | $0.7439 | $0.7184 | $0.728 | 1.52M |
| Aug 17, 2026 | $0.74 | $0.795 | $0.7394 | $0.7442 | 2.43M |
| Aug 14, 2026 | $0.75 | $0.767 | $0.71 | $0.7398 | 7M |
| Aug 13, 2026 | $0.855 | $0.9138 | $0.79 | $0.79 | 4.38M |
The latest Smart Investors Daily articles mentioning QSI.
QSI research
Company profile and research snapshot.
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 5, 2026 | Canaccord Genuity | Hold | — |
| Dec 22, 2025 | Canaccord Genuity | Hold | — |
| Oct 27, 2025 | Canaccord Genuity | Hold | — |
| Sep 9, 2025 | Canaccord Genuity | Hold | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Canaccord Genuity analyst Kyle Mikson maintains Quantum-Si (NASDAQ:QSI) with a Hold and lowers the price target from $1.5 to $1.
ChartMill · Mar 3, 2026
Quantum-Si reports Q4 revenue miss, lowers 2026 outlook to focus on launching its next-generation Proteus protein analysis platform.
Benzinga · Mar 3, 2026
Here's a look at why Quantum-Si stock is slipping after Q4 earnings.
Benzinga · Mar 3, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning QSI.